Braidwell »

Structure Therapeutics shares owned by Braidwell

Quarter-by-quarter ownership of Structure Therapeutics (GPCR) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Structure Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Structure Therapeutics held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Structure Therapeutics by Braidwell

Quarter filed Position value Share count Share price at filing
2023-12-31 $11M 280k 40.76

More positions owned by Braidwell

Guardant Health Note 11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Ascendis Pharma A/s Note 2.250% 4/0 (Principal)
Exact Sciences Corp Note 0.375% 3/0 (Principal)
Novocure Note 11/0 (Principal)
Neurocrine Biosciences (NBIX)
Vaxcyte (PCVX)
Xenon Pharmaceuticals (XENE)
Nuvasive Note 0.375% 3/1 (Principal)
Insulet Corp Note 0.375% 9/0 (Principal)
Tandem Diabetes Care Note 1.500% 5/0 (Principal)
Day One Biopharmaceuticals I (DAWN)
Irhythm Technologies (IRTC)
Argenx Se Sponsored Adr (ARGX)
Bridgebio Pharma Note 2.250% 2/0 (Principal)

View all positions for Braidwell

Top funds holding Structure Therapeutics

Wellington Management Company
venBio Select Advisor
Federated Investors
Avidity Partners Management
T. Rowe Price Associates
Henderson Group
Citadel Advisors
Casdin Capital
Logos Global Management
Sc China Holding
Deerfield Management Company
BVF
Caption Management
Franklin Resources
RA Capital Management

View all funds holding Structure Therapeutics